Lp(a) and coronary disease: Rules of engagement - When to measure and how to treat

South African Medical Journal

Volumn 99, Issue 7, 2009, Pages 502-504

  Jayasinghe, R ^a,c,e   Kostner, K M ^b,d  

^a GRIFFITH UNIVERSITY   (Australia)

^b MATER HOSPITAL   (Australia)

^c BOND UNIVERSITY   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e GOLD COAST UNIVERSITY HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; NICOTINIC ACID DERIVATIVE;

APHERESIS; ARTICLE; ATHEROGENESIS; CORONARY ARTERY DISEASE; CORONARY RISK; DRUG EFFICACY; DRUG MECHANISM; ETHNIC DIFFERENCE; GENETIC HETEROGENEITY; HUMAN; LIPOPROTEIN BLOOD LEVEL; PATIENT ASSESSMENT; PATIENT SELECTION; PRACTICE GUIDELINE; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN SYNTHESIS REGULATION; PROTEINURIA;

EID: 70049103078     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Berg K. A new serum type system in man: the Lp system. Acta Pathol Microbiol Scand 1963; 59: 362-362.
2. Kostner KM, Kostner GM. Lipoprotein (a): Still an enigma? Curr Opin Lipidol 2002; 13(4): 391-396.
3. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary artery disease: meta-analysis of prospective studies. Circulation 2000; 102: 1082-1085.
4. Enas EA, Senthilkumar A. Coronary artery disease in Asian Indians: An update and review. Int J Cardiol 2001; 1: 2.
5. Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005; 353(1): 46-57.
6. Sandholzer C, Halman D, Saha N, et al. Effect of apolipoprotein (a) polymorphism on the lipoprotein (a) concentration in seven ethnic groups. Human Genet 1991; 86: 607-614.
7. Ohira T, Schreiner PJ, Morrisett JD, et al. Lipoprotein(a) and incident ischemic stroke: The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 2006; 37(6): 1407-1412.
8. Ridker PM, Hennekens CA, Stampfer MJ. A prospective study of Lp(a) and the risk of myocardial infarction. JAMA 1993; 270: 2195-2199.
9. Marcovina S, Koschinsky ML, Albers J, et al. Report of the National Heart Lung and Blood Institute workshop on lipoprotein(a) and cardiovascular disease. Recent advances and future directions, Clin Chem 2003; 49: 1788-1796.
10. Dahlen CG. Lipoprotein(a) in cardiovascular disease: Review article and viewpoint. Atherosclerosis 1994; 108: 111-126.
11. Enas EA. Risk of primary and recurrent acute myocardial infarction from lipoprotein (a). J Am Coll Cardiol 1997; 29: 887-889.
12. Schlueter W, Keilani T, Batlle DC. Metabolic effects of ACE inhibitors: focus on the reduction of cholesterol and lipoprotein (a) by fosinopril. Am J Cardiol 1993; 72(20): 37-44.
13. Hoffmann U, Derfler K, Haas M, et al. Effects of combined low-density lipoprotein apheresis and aggressive statin therapy on coronary calcified plaque as measured by computed tomography. Am J Cardiol 2003; 91: 461-464.
14. Mensah GA. Ischaemic heart disease in Africa. Heart 2008; 94: 836-884.